These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38307136)

  • 1. Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies.
    Moedas MF; Simões RJM; Silva MFB
    Biochem Pharmacol; 2024 Apr; 222():116034. PubMed ID: 38307136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperammonemia in Inherited Metabolic Diseases.
    Ribas GS; Lopes FF; Deon M; Vargas CR
    Cell Mol Neurobiol; 2022 Nov; 42(8):2593-2610. PubMed ID: 34665389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
    Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
    J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ammonia metabolism and hyperammonemic disorders.
    Walker V
    Adv Clin Chem; 2014; 67():73-150. PubMed ID: 25735860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.
    Häberle J
    Arch Biochem Biophys; 2013 Aug; 536(2):101-8. PubMed ID: 23628343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the treatment of hyperammonemia.
    Matoori S; Leroux JC
    Adv Drug Deliv Rev; 2015 Aug; 90():55-68. PubMed ID: 25895618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ammoniagenic Action of Valproate without Signs of Hepatic Dysfunction in Rats: Possible Causes and Supporting Evidence.
    Alilova G; Tikhonova L; Montoliu C; Kosenko E
    Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia.
    Soria LR; Allegri G; Melck D; Pastore N; Annunziata P; Paris D; Polishchuk E; Nusco E; Thöny B; Motta A; Häberle J; Ballabio A; Brunetti-Pierri N
    Proc Natl Acad Sci U S A; 2018 Jan; 115(2):391-396. PubMed ID: 29279371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia.
    Soria LR; Brunetti-Pierri N
    J Inherit Metab Dis; 2019 Nov; 42(6):1097-1104. PubMed ID: 30671986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperammonemia in urea cycle disorders: role of the nephrologist.
    Mathias RS; Kostiner D; Packman S
    Am J Kidney Dis; 2001 May; 37(5):1069-80. PubMed ID: 11325692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Ketoglutaramate: an overlooked metabolite of glutamine and a biomarker for hepatic encephalopathy and inborn errors of the urea cycle.
    Cooper AJ; Kuhara T
    Metab Brain Dis; 2014 Dec; 29(4):991-1006. PubMed ID: 24234505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias.
    Lichter-Konecki U; Nadkarni V; Moudgil A; Cook N; Poeschl J; Meyer MT; Dimmock D; Baumgart S
    Mol Genet Metab; 2013 Aug; 109(4):354-9. PubMed ID: 23791307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.
    Holecek M
    Metab Brain Dis; 2014 Mar; 29(1):9-17. PubMed ID: 23996300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical findings of patients with hyperammonemia affected by urea cycle disorders with hepatic encephalopathy.
    Lopes FF; Sitta A; de Moura Coelho D; Ribas GS; Faverzani JL; Dos Reis BG; Wajner M; Vargas CR
    Int J Dev Neurosci; 2022 Dec; 82(8):772-788. PubMed ID: 36129623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting autophagy for therapy of hyperammonemia.
    Soria LR; Brunetti-Pierri N
    Autophagy; 2018; 14(7):1273-1275. PubMed ID: 30035657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated cellular redox status during hyperammonemia causes mitochondrial dysfunction and senescence by inhibiting sirtuin-mediated deacetylation.
    Mishra S; Welch N; Karthikeyan M; Bellar A; Musich R; Singh SS; Zhang D; Sekar J; Attaway AH; Chelluboyina AK; Lorkowski SW; Roychowdhury S; Li L; Willard B; Smith JD; Hoppel CL; Vachharajani V; Kumar A; Dasarathy S
    Aging Cell; 2023 Jul; 22(7):e13852. PubMed ID: 37101412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonhepatic Hyperammonemia With Septic Shock: Case and Review of Literature.
    Dalsania N; Kundu S; Patti RK; Somal N; Kupfer Y
    J Investig Med High Impact Case Rep; 2022; 10():23247096221101855. PubMed ID: 35596541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders.
    Summar ML; Mew NA
    Pediatr Clin North Am; 2018 Apr; 65(2):231-246. PubMed ID: 29502911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ammonia toxicity and its prevention in inherited defects of the urea cycle.
    Walker V
    Diabetes Obes Metab; 2009 Sep; 11(9):823-35. PubMed ID: 19531057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.